Balch’s perspective underscores the broader affordability crisis facing working families and highlights how rising premiums ...

In today’s Pharma Pulse, the FDA and EMA synchronize on AI standards, a potential divide in pricing strategy occurs, and ...

Oral semaglutide was approved by the FDA in December 2025 as a once-daily pill (25 mg), intended to limit excess body weight ...

According to Alan Balch, PhD, CEO of the Patient Advocate Foundation and the National Patient Advocate Foundation, rising ...

In today’s Pharma Pulse, Novartis calls for a shift from "cost-containment" to structural reform, hospital mergers hit their ...

In the final part of his Pharma Commerce video interview, Franco Stevanato, CEO of Stevanato Group, explains that with plant ...

In today’s Pharma Pulse, President Trump unveils a patient payment plan, the FDA flags a rare seizure risk for several ...

In the second part of his Pharma Commerce video interview, Franco Stevanato, CEO of Stevanato Group, describes how from FDA ...

In the third part of his Pharma Commerce video interview, Franco Stevanato, CEO of Stevanato Group, shares how automatic ...

The company’s latest preview report projects a guarded rebound for biopharma, as investor confidence returns and M&A activity ...

The pharma giant will invest in a 35,000-square-foot RLT manufacturing site in Winter Park, FL as part of its $23 billion US ...

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, ...